Thrombosis Research

Article	Citations
Major in-hospital bleeding in patients with pulmonary embolism treated with systemic thrombolysis	89
Unveiling the predictive capacity of inflammatory and platelet markers for central retinal artery occlusion	64
Vaccine-induced immune thrombocytopenia and thrombosis after mRNA-1273 booster vaccination	64
Acute and subacute effects of strenuous exercise on platelet aggregation, coagulation and fibrinolysis in patients with stable coronary artery disease	63
A novel role of acellular hemoglobin in hemolytic thrombosis	63
Accuracy of the functional, flow cytometer-based Emo-Test HIT Confirm® for the diagnosis of heparin-induced thrombocytopenia	50
PO-08: Characterisation of plasma extracellular vesicles in myeloproliferative neoplasms	49
PO-51: Kaposiform hemangioendothelioma is associated with platelet functional abnormalities that persist in patients even after complete blood cell count recovery	48
PO-39: Superior vena cava stenting: an effective and safe therapeutic choice for the treatment of superior vena cava syndrome in lung cancer patients	48
Pre-admission anticoagulant therapy and mortality in hospitalized COVID-19 patients: A retrospective cohort study	46
Validation of the Academic Research Consortium for High Bleeding Risk criteria in Chinese patients with atrial fibrillation and acute coronary syndrome or undergoing percutaneous coronary intervention	46
Quality and predictors of oral anticoagulation therapy with vitamin K antagonists in adult congenital heart disease: TTR and INR variability	41
DOACs: A perfect fit for patients with bariatric surgery?	41
Decreased patency of transjugular intrahepatic portosystemic shunts performed for splanchnic vein thrombosis in patients with myeloproliferative neoplasms	40
Is all collagen the same for platelet testing? Editorial on “Platelet collagen receptors and their role in modulating platelet adhesion patterns and activation on alternatively processed collagen subs	37
Inappropriate low dosing of direct oral anticoagulants in older patients with non-valvular atrial fibrillation: Impact on plasma drug levels	37
Corrigendum to “Repurposing of rilpivirine for preventing platelet β3 integrin-dependent thrombosis by targeting c-Src active autophosphorylation” [Thromb. Res. 229 (2023) 53–68]	36
Rivaroxaban plus aspirin versus acenocoumarol to manage recurrent venous thromboembolic events despite systemic anticoagulation with rivaroxaban	35
Clonal hematopoiesis and cardiovascular disease in cancer patients and survivors	33
Crosstalk between hemostasis and immunity in cancer pathogenesis	33
Regulation of fibrinogen synthesis	32
Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors	31
Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: A randomized trial in 108 patients	31
Investigation of the impact of antithrombin deficiency on the inflammatory response: Results from a single centre cohort study	30
Clinical outcomes of cancer-associated isolated superficial vein thrombosis in daily practice	29

Pulmonary embolism: Age specific temporal trends in incidence and mortality in Denmark 1999–2018	29
Sex disparities of clinical manifestations in acute pulmonary embolism and predictive value for in-hospital mortality: Insights from CURES	28
Predicting post-discharge venous thromboembolism and bleeding among medical patients: External validation of a novel risk score utilizing ubiquitous biomarkers	28
PO-18: Myocardial infarction and risk of cancer	27
PO-40: Therapeutic approaches of superior vena cava syndrome in patients with non-small cell lung cancer (NSCLC)	27
PO-22: Rate of venous thromboembolism events in cancer patients treated by radiation therapy: the Radiation-Induced Thrombosis study	26
PO-60: Comparison of inferior vena cava (IVC) filter use and outcomes between cancer and non-cancer patients in a single-center cohort	26
PO-56: Low molecular weight heparin beyond 12 months in patients with cancer associated thrombosis: CAT-LONG study	26
Preface to the Proceedings of the 11th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2022	25
Predicting functional outcomes after acute ischemic stroke – Is thrombelastography useful outside perioperative bleeding management?	25
Safety of fixed-dose heparin titration boluses in underweight patients	25
Vaccine-induced immune thrombotic thrombocytopenia and patients with cancer	24
In vitro procoagulant effects of Gla-domainless factor Xa in factor XI-deficient and factor IX-deficient plasma	24
Large deletions and small insertions and deletions in the factor VIII gene predict unfavorable immune tolerance induction outcome in people with severe hemophilia A and high-responding inhibitors	24
CT coronary calcium score is a prognostic marker in acute pulmonary embolism	23
Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance	23
Incidence and mortality due to thromboembolic events during the COVID-19 pandemic: Multi-sourced population-based health records cohort study	23
Canadian Perspective on Superficial Vein Thrombosis in Pregnancy and Postpartum: Interim Results from a Tertiary Care Centre	22
Prosthetic valve dysfunction in patients with mechanical heart valves: Results from the Emergency Salam Centre cohort	22
Isolated subsegmental pulmonary embolism identification based on international classification of diseases (ICD)-10 codes and imaging reports	22
Performance of the Bova score in predicting short-term all-cause mortality in patients with pulmonary embolism and normal blood pressure. A systematic review and meta-analysis	21
Corrigendum to “Rivaroxaban or apixaban in fragile patients with acute venous thromboembolism” [Thromb. Res. 193 (2020) 160–165]	21
D-dimer and risk of venous thromboembolism recurrence: Comparison of two studies with similar designs but different laboratory and clinical results	21
Editorial Board	21
Letter to the editors-in-chief reply to: Solinas et al. Venous and arterial thromboembolic events with immune check point inhibitors: A systematic review	21
Coagulation profile in newly diagnosed T-cell acute lymphoblastic leukemia	20
Letter to the editor regarding the article “Platelet activity, coagulation, and fibrinolysis in long-term users of anabolic-androgenic steroids compared to strength-trained athletes”	20
Optimal enoxaparin dosing strategies for venous thromboembolism prophylaxis and treatment of high body weight patients	20
The impact of different prophylactic anticoagulation doses on the outcomes of patients with COVID-19	20
Statin use and mortality in patients with deep vein thrombosis. Data from the RIETE Registry	20
Clinical and genetic features of Chinese pediatric patients with severe congenital protein C deficiency who first presented with purpura fulminans: A case series study and literature review	20
Influence of PAR-1 in patients with non-valvular atrial fibrillation: The antiplatelet effect of dabigatran	20
Influence of sex on development of thrombosis in patients with COVID-19: From the CLOT-COVID study	20
Incidence and impact of disseminated intravascular coagulation in COVID-19 a systematic review and meta-analysis	19
Resistance to activated protein C and impaired TFPI activity in women with previous hormone-induced venous thromboembolism	19
Does thromboelastography predict bleeding in patients treated with clopidogrel or ticagrelor in off-pump coronary artery bypass grafting?	19
Platelets activated by different agonists produce microparticles with the same procoagulant properties	19
To aPTT or not to aPTT: Evaluating the optimal monitoring strategy for unfractionated heparin	19
Pulmonary embolism bleeding score index (PEBSI): A new tool for the detection of patients with low risk for major bleeding on thrombolytic therapy	18
The role of platelets in heat-related illness and heat-induced coagulopathy	18
Real-time risk stratification in acute pulmonary embolism: the utility of RV/LV diameter ratio	18
Venous thromboembolism in hematopoietic stem cell transplantation: A narrative review	18
Myocardial ischemia-reperfusion injury released cellular fibronectin containing domain A (CFN-EDA): A destructive positive loop amplifying arterial thrombosis formation and exacerbating myocardial rep	18
Comparison of absolute immature platelet count to the PLASMIC score at presentation in predicting ADAMTS13 deficiency in suspected thrombotic thrombocytopenic purpura	18
Driver gene KRAS aggravates cancer-associated stroke outcomes	18
Intrinsic coagulant potential modulates anticoagulant efficacy of rivaroxaban	17
Association between neutrophil extracellular traps (NETs) and thrombosis in antiphospholipid syndrome	17
Stroke mortality in cancer survivors: A population-based study in Japan	17
A risk-stratified approach to venous thromboembolism prophylaxis with aspirin or warfarin following total hip and knee arthroplasty: A cohort study	17
Main features of ischemic stroke in patients with acute immune-mediated thrombotic thrombocytopenic purpura	17

Pulmonary embolism diagnostic strategies in patients with COPD exacerbation: Post-hoc analysis of the PEP trial	17
Changes in haemostasis and inflammatory markers after mRNA BNT162b2 and vector Ad26.CoV2.S SARS-CoV-2 vaccination	17
OC-10: Plasmatic von Willebrand factor encapsulates blood circulating melanoma cells to prevent their hematogenous metastasis	17
Low-dose immune tolerance induction therapy in severe hemophilia a children in China: Starting earlier resulted in better inhibitor eradication outcomes	17
Don't let D-dimer fool you: Elevated D-dimer plasma levels should not imply ‘hyperfibrinolysis’	17
A survey on clinical practice in monitoring and management of bleeding in children with haemophilia A on emicizumab prophylaxis in the PedNet centres	17
Editorial Board	17
Editorial Board	16
Suitability and readiness assessment of organizational resources for the implementation of gene therapy in hemophilia in Spain and Portugal: A survey-based study	16
A noncanonical splicing variant c.875-5 T > G in von Willebrand factor causes in-frame exon skipping and type 2A von Willebrand disease	16
Procoagulant phenotype induced by oxidized high-density lipoprotein associates with acute kidney injury and death	16
Risk of venous thromboembolism in women with endometriosis	16
Barriers and facilitators for adherence to direct oral anticoagulants in patients with atrial fibrillation: A qualitative approach	16
Rotational thromboelastometry as a biomarker for mortality — The Maastricht Intensive Care COVID cohort	16
Anticoagulation plus antiplatelet therapy versus anticoagulation alone following iliac vein stent implantation in acute and subacute deep vein thrombosis: A multicenter study with propensity score mat	15
Accuracy of physical examination in detecting central venous catheter-associated thrombosis in critically ill children	15
Hypothermia causes platelet activation in the human spleen	15
Intracoronary antithrombotic therapy during primary percutaneous coronary intervention in patients with STEMI: A systematic review and network meta-analysis	15
Abstracts from the CanVECTOR 2024 Annual Conference October 25th, 2024	15
Hsa_circ_0001020 accelerates the lower extremity deep vein thrombosis via sponging miR-29c-3p to promote MDM2 expression	15
Effect of lupus anti-coagulant and antiphospholipid antibodies on clot waveform analysis parameters	15
Regulation of coagulation activation in newly diagnosed AML by the heme enzyme myeloperoxidase	15
The long haul COVID-19 arterial thrombosis	15
Thromboelastography as a predictor of functional outcome in acute ischemic stroke patients undergoing endovascular treatment	15
Thrombosis and thrombocytopenia in antiphospholipid syndrome: their association with mean platelet volume and hematological ratios	15
Optimizing therapeutic enoxaparin in preterm neonates and infants	15
Elevated plasma D-dimer levels are associated with risk of future incident venous thromboembolism	15
Atrial fibrillation and peripheral arterial disease define MPN patients with very high risk of thrombosis	15
Mental, emotional and social dimensions of quality of life and their relationship with physical and functional status in adults with haemophilia	15
Association between the simplified Pulmonary Embolism Severity Index (sPESI) score and hospitalization in emergency department patients diagnosed with pulmonary embolism	15
Editorial Board	14
DOACs plasma levels in relation to clinical outcome. How far have we come?	14
PO-37: A study of the evolution of radiological features of untreated small volume pulmonary embolism (PE) in cancer patients	14
Thrombocytopenia is associated with a dysregulated host response in severe COVID-19	14
PO-30: Chemotherapeutic agents temozolomide and lomustine induce procoagulant activity of glioblastoma cell lines in vitro	14
Letter: In response to a recent letter by Prior et al.	14
Clinical and economic burden of immune tolerance induction in entire patients with hemophilia A: Insights from a real-world Korean setting	14
PO-23: Upper extremity deep vein thrombosis in cancer patients: our experience	14
PO-54: Preliminary evaluation of venous thromboembolic risk in patients with colorectal cancer from the CARTAGO study	13
ROS-driven structural and functional fibrinogen modifications are reverted by interleukin-6 inhibition in Giant Cell Arteritis	13
A Predictive Model to Identify Pulmonary Embolism in Unselected Emergency Department Patients: Model Validation and Improvement During the COVID Era	13
Postoperative myocardial injury and platelet reactivity in patients undergoing vascular surgery: The platelet reactivity and postoperative myocardial injury after major vascular surgery (PROMISE) stud	13
Contact activated kallikrein generation is reduced six months after gastric bypass	13
Reference values of coagulation assays performed for thrombophilia screening after a first venous thrombosis and their intra-patient associations	13
Acquired von Willebrand syndrome secondary to lymphoproliferative disorders: A case series from two French centers	13
The Attend-PE model: A feasibility study of a structured follow-up care model for patients with pulmonary embolism.	13
Elevated plasma levels of factor VIII enhance arterial thrombus formation on erosive smooth muscle cell-rich neointima but not normal intima in rabbits	13
Covid-19 vaccination, adverse events, and detection of antibodies	13
18F-Fluorodeoxyglucose positron emission/computed tomography for occult cancer among patients with unprovoked venous thromboembolism: What do we know?	13
Incidence and impact of venous thromboembolism in hospitalized patients with Crohn's disease	13
Protein disulfide isomerase 1 (PDIA1) regulates platelet-derived extracellular vesicle release	13
Corrigendum to “The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management” [Thromb. Res., 194, October 2020, Pages 101–115]	13
PO-63: Edoxaban effect in a breast cancer patient with liver arterial infusion chemotherapy (LAIC) and both jugular vein and hepatic artery thrombosis: a unique clinical case	12
Hemostatic considerations for gender affirming care	12
Performance of age-adjusted and fixed threshold D-dimer to exclude DVT in those with low pre-test probability – Single centre experience	12
PO-47: Prevention and treatment of recurrent trombosis after reconstruction of major vessels	12
PO-57: Venous thromboembolism recurrence during anticoagulant treatment in gastrointestinal cancer patients	12
Safety and efficacy of apixaban as thromboprophylaxis in myeloma patients receiving chemotherapy: A prospective cohort study	12
PO-29: Coagulation and circulating tumour cells as pharmacodynamic biomarkers of response to aromatase inhibitors in breast cancer	12
Editorial Board	12
Risk factors for hospital acquired venous thromboembolism in congenital heart disease patients: A report from the children's hospital acquired thrombosis (CHAT) consortium	12
Evaluation of definitions for oral anticoagulant-associated major bleeding: A population-based cohort study	11
Challenging anticoagulation cases: A case of heparin-induced-thrombocytopenia in the first trimester of pregnancy	11
Platelets provide robustness of spatial blood coagulation to the variation of initial conditions	11
Outcomes of IVF treatments in women with antiphospholipid antibodies or antiphospholipid syndrome	11
Characteristics and outcome of a territory-wide cohort study of patients with acquired hemophilia A in Hong Kong	11
Identification of two de novo variants causing inherited antithrombin deficiency by quantitative analysis of variant alleles	11
Newly developed modified diluted prothrombin time reagent: A multi-centre validation in patients with non-valvular atrial fibrillation under direct oral anticoagulant therapy	11
A systematic review and meta-analysis of periprocedural bridging for patients with mechanical heart valves undergoing non-cardiac interventions	11
DOAC Score for prediction of major bleeding in patients with venous thromboembolism: Findings from the RIETE registry	11
Air pollution impacts on in-hospital case-fatality rate of ischemic stroke patients	11
Thymidine phosphorylase mediates SARS-CoV-2 spike protein enhanced thrombosis in K18-hACE2TG mice	11
Editorial Board	11
Low recurrent thrombosis rates in single positive antiphospholipid syndrome regardless of type of anticoagulation	11
Risks of bleeding and thromboembolic events in patients undergoing colonoscopy on uninterrupted and interrupted anticoagulant therapy in real-world setting	11
The contact system in chronic kidney disease and hemodialysis – A cross-sectional study	11
The course of pulmonary embolism in individuals recovered from COVID-19	11
Venous thromboembolism in women with hormone-dependent breast cancer. To continue or discontinue hormonal treatment? Insights from the RIETE registry	10
Prognostic role of serial electrocardiographic changes in patients with acute pulmonary embolism. Data from the Italian Pulmonary Embolism Registry	10
Characterization of a prothrombotic phenotype using thrombin generation and thrombin activity in cirrhosis and portal hypertension	10

Can edoxaban be used at extremes of bodyweight and in patients with a creatinine clearance ≥95 ml/min? – A population pharmacokinetic analysis	10
Long-term VTE treatment with rivaroxaban: Results from the DRESDEN NOAC REGISTRY	10
Machine learning prediction of venous thromboembolism after surgeries of major sellar region tumors	10
PO-04: Thrombin generation and D-dimer significantly predict for early disease progression and mortality in patients with gastrointestinal cancer	10
Mitochondrial DNA copy number and its association with venous thromboembolism in patients with cancer	10
Thromboprophylaxis in COVID-19: Early initiation might be as important as optimal dosing	10
Therapeutic anticoagulation in COVID-19 patients	10
Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19	10
CXCL13/CXCR5 axis facilitates TFH expansion and correlates with disease severity in adults with immune thrombocytopenia	10
Perinatal stroke and hypofibrinogenemia: Is the new missense fibrinogen variant γ p.Gly310Glu the cause of the procoagulant state?	10
Long-term clinical outcomes in older patients with acute venous thromboembolism who have renal impairment	10
Shiga toxin down-regulates ERG protein in endothelial cells and impairs angiogenesis	10
Association of antithrombotic medications and composition of thrombi retrieved by mechanical thrombectomy in acute ischemic stroke	10
Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial	10
Major cardiovascular events after COVID-19, event rates post-vaccination, antiviral or anti-inflammatory therapy, and temporal trends: Correspondence	10
PO-11: Risk of major bleeding in cancer patients with ischemic stroke treated with thrombolysis	10
Editorial Board	10
Natural history of untreated acute pulmonary embolism in patients with cancer: A retrospective cohort of missed pulmonary emboli	10
Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation - A meta-analysis	10
Performance of the 4-Level Pulmonary Embolism Clinical Probability Score (4PEPS) in the diagnostic management of pulmonary embolism: An external validation study	10
Prothrombotic disorders in non-cirrhotic, non-tumoral portal vein thrombosis	10
COVID-19 associated Venous Thromboembolism (VTE) burden in Black women: Findings of Veterans Affairs COVID-19 Shared Data	10
Neutrophil extracellular traps formation may be involved in the association of propranolol with the development of portal vein thrombosis	10
Every 6 seconds in Europe	10
Prevention of post-thrombotic syndrome with rosuvastatin: A multicenter randomized controlled pilot trial (SAVER)	10
Dynamics of troponins and 30-day mortality in hospitalized patients with pulmonary embolism	10
Association between coagulation activity and clinical and imaging outcomes in acute ischemic stroke patients - A sub-study of the MR CLEAN NO-IV trial	10
Understanding European patterns of deprescribing antithrombotic medication during end-of-life care in patients with cancer	10
Differential regulation of human thrombospondin-1 upon systemic desmopressin versus endotoxin challenge	10
Added IMPACT: The first successful natural birth using certolizumab in obstetric APS	10
Identification of hematuria with a natural language processing model and validation of hematuria diagnosecodes	10
Incidence and risk factors of post-thrombotic syndrome in patients with isolated calf vein thrombosis. Findings from the GARFIELD-VTE registry	9
Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination	9
Tissue factor expression in monocyte subsets during human immunothrombosis, endotoxemia and sepsis	9
Scoping review of current evidence on the incidence of Venous thromboembolism (VTE) in the East Asian population	9
Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial	9
In-hospital outcomes of Ticagrelor versus Clopidogrel in high bleeding risk patients with acute coronary syndrome: Findings from the CCC-ACS project	9
Early immune tolerance induction is a unique predictor of favorable outcomes in hemophilia A children with intron 22 inversion and high-responding inhibitors	9
Impact of direct oral anticoagulants on evolution of post-thrombotic syndrome	9
Long term recovery of right ventricular function after treatment of intermediate and high risk pulmonary emboli	9
Efficacy and safety of antithrombin or recombinant human thrombomodulin in the treatment of disseminated intravascular coagulation: A systematic review and meta-analysis	9
Molecular basis of clot retraction and its role in wound healing	9
Prognostic value of an automated thrombin generation assay in COVID-19 patients entering hospital: A multicentric, prospective observational study	9
Management strategies and clinical outcomes of venous thromboembolism in patients with antiphospholipid syndrome in the direct oral anticoagulant era: Insight from the COMMAND VTE Registry-2	9
Reduction of venous thromboembolic events in COVID-19 patients: Which role for IL-6 antagonists?	9
Effectiveness and safety of anticoagulants among venous thromboembolism cancer patients with and without brain cancer	9
The differential formation and composition of leukocyte-platelet aggregates induced by various cellular stimulants	9
Effect of regular exercise training on platelet function in patients with cardiovascular disease and healthy individuals: A systematic review	9
Tigecycline-associated hypofibrinogenemia: A single center, retrospective, controlled study	9
Prognosis after cerebral venous thrombosis: Mortality during initial admission and at 30 days and one year after discharge in a large Canadian population-based cohort	9
Exploration of rotational thromboelastometry (ROTEM) to characterize the coagulation profiles of newly diagnosed pediatric leukemia patients	9
Not all patent foramen ovales are alike!	9
Who are we bridging? Description of warfarin patients receiving injectable bridging therapy	9
Adjusted global antiphospholipid syndrome score (aGAPSS) is useful to predict relapses in patients with retinal vein occlusion	9
Copyright	9
Defibrotide mitigates endothelial cell injury induced by plasmas from patients with COVID-19 and related vasculopathies	9
DOAC drug levels: Does “knowing” lead to safer care?	9
Outcomes of isolated distal thrombosis managed with serial compression ultrasonography	9
Health-related quality of life associated with warfarin and direct oral anticoagulants in venous thromboembolism	9
Editorial Board	9
Anticoagulation with argatroban using hemoclot™ targets is safe and effective in CARDS patients receiving venovenous extracorporeal membrane oxygenation: An exploratory bi-centric cohort study	9
Editorial Board	9
Cerebral venous thrombosis and thrombocytopenia post-COVID-19 vaccination	9
Pulmonary infarction in acute pulmonary embolism	9
To clot, or not to clot: The dilemma of hormone treatment options for menopause	8
Osimertinib-related venous thromboembolism in non small lung cancer	8
Dielectric blood coagulometry to evaluate coagulation activity in patients prescribed factor Xa inhibitors undergoing elective surgery: A prospective observational study	8
Antiplatelet and anticoagulant therapies in hereditary hemorrhagic telangiectasia: A large French cohort study (RETROPLACOTEL)	8
Major cardiovascular events after COVID-19, event rates post-vaccination, antiviral or anti-inflammatory therapy, and temporal trends: Rationale and methodology of the CORONA-VTE-Network study	8
Is pulmonary embolism occurring after SARS COV-2 vaccination provoked or unprovoked?	8
PO-24: Incidence of venous thromboembolism following head and neck surgery stratified according to cancer: a Danish nation-wide cohort study	8
Venous thromboembolism in pediatric patients with sickle cell disease: A north American survey on experience and management approaches of pediatric hematologists	8
COVID-19 venous thromboembolism prophylaxis guidelines in pediatrics	8
Effect of α2-plasmin inhibitor heterogeneity on the risk of venous thromboembolism	8
Clinical and endoscopic findings in patients with acute gastrointestinal bleeding associated with direct oral anticoagulants: Results from a single-center prospective cohort study	8
The efficacy and safety of andexanet alfa in the treatment of anticoagulation-related major bleedings: An Italian perspective	8
Editorial Board	8
SARS-CoV-2 infection, vaccination and acquired hemophilia: Correspondence	8
D-dimer driven deep vein thrombosis prophylaxis strategy for hospitalized patients with COVID-19	8
Development and validation of a clinical prediction model for post thrombotic syndrome following anticoagulant therapy for acute deep venous thrombosis	8
Reply to the letter to the editor ‘Reply to Solinas et al, venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review’ by Frere et al.	8
Patients with multiple myeloma and monoclonal gammopathy of undetermined significance have variably increased thrombin generation and different sensitivity to the anticoagulant effect of activated pro	8
S62798, a potent TAFIa inhibitor, accelerates endogenous fibrinolysis in a murine model of pulmonary thromboembolism	8
Evaluation of hemostatic abnormalities in patients who underwent major hepatobiliary pancreatic surgery using activated partial thromboplastin time-clot waveform analysis	8
Depression and anxiety up to two years after acute pulmonary embolism: Prevalence and predictors	8
Management options for pediatric venous thromboembolic disease: Beyond anticoagulation with endovascular therapies	8
Risk of thromboembolism according to statin treatment in patients with cancer: A nationwide nested case-control study	8
Therapeutic anticoagulation in COVID-19 patients	8
PO-43: Pharmacological thromboprophylaxis to prevent venous thromboembolism in ambulatory patients with cancer undergoing antineoplastic drugs in real world clinical practice: a cohort study	8
A RIETE registry analysis of patients with upper extremity deep vein thrombosis and thoracic outlet syndrome	8
Initiation of anticoagulation in atrial fibrillation by primary care physicians: Results of a telephone survey	8
Association between genetic mutations and risk of venous thromboembolism in patients with solid tumor malignancies: A systematic review and meta-analysis	8
Chemotherapy alters thrombomodulin and factor VIIIc expression resulting in acquired activated protein C resistance and enhanced thrombin generation in cancer associated thrombosis	7
Phenotype, genotype, and laboratory assessment of congenital fibrinogen disorders: Data from the Rare Bleeding disorders in the Netherlands study	7
Risk of venous and arterial thromboembolic events in women with advanced breast cancer treated with CDK 4/6 inhibitors: A systematic review and meta-analysis	7